Sandoz has confirmed the European launch of its Pyzchiva (ustekinumab) biosimilar rival to Stelara. The introduction of the Samsung Bioepis-partnered biosimilar comes just days after Stada and Alvotech’s Uzpruvo version hit the market at the start of this week.
Pyzchiva – which was approved in Europe earlier this year (Also see "Sandoz And Samsung Celebrate Stelara Rival’s EU...






